Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00389207
First received: October 17, 2006
Last updated: December 9, 2013
Last verified: December 2013
Results First Received: January 13, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: HIV Infections
Interventions: Drug: nevirapine bid
Drug: nevirapine qd
Drug: atazanavir

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Nevirapine QD Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)
Nevirapine BID NVP 200mg BID on a background of the fixed combination Truvada®
Atazanvir/Ritonavir Atazanvir 300mg QD boosted by ritonavir 100mg QD (ATZ/r) on a background of the fixed combination Truvada®

Participant Flow:   Overall Study
    Nevirapine QD   Nevirapine BID   Atazanvir/Ritonavir
STARTED   188 [1]   188 [2]   193 
COMPLETED   125   116   152 
NOT COMPLETED   63   72   41 
Adverse Event                26                32                10 
Protocol Violation                3                1                4 
Lost to Follow-up                12                9                7 
Withdrawal by Subject                5                7                11 
Not specified                17                23                9 
[1] 3 patients were randomized to NVP QD but not treated and so not part of the Full Analysis Set (FAS)
[2] 4 patients were randomized to NVP BID but not treated and so are not part of the FAS



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Nevirapine QD Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)
Nevirapine BID NVP 200mg BID on a background of the fixed combination Truvada®
Atazanvir/Ritonavir ATZ/r on a background of the fixed combination Truvada®
Total Total of all reporting groups

Baseline Measures
   Nevirapine QD   Nevirapine BID   Atazanvir/Ritonavir   Total 
Overall Participants Analyzed 
[Units: Participants]
 188   188   193   569 
Age 
[Units: Years]
Mean (Standard Deviation)
 38.4  (9.7)   40.0  (10.5)   37.6  (9.5)   38.6  (9.9) 
Gender 
[Units: Participants]
       
Female   36   25   31   92 
Male   152   163   162   477 
Baseline HIV viral load category 
[Units: Participants]
       
Baseline HIV viral load ≤ 100,000 copies/mL   71   71   65   207 
Baseline HIV viral load > 100,000 copies/mL   117   117   128   362 
Baseline log10 HIV viral load [1] 
[Units: Log 10 Copies/mL]
Mean (Standard Deviation)
 5.1  (0.7)   5.1  (0.6)   5.1  (0.7)   5.1  (0.7) 
[1] 185 NVP QD patients, 188 NVP BID patients and 192 ATZ/R patients had data
Baseline CD4+ cell count [1] 
[Units: Cells/mm^3]
Mean (Standard Deviation)
 183.3  (95.5)   202.9  (93.6)   193.2  (95.8)   193.2  (95.1) 
[1] 185 NVP QD patients, 188 NVP BID patients and 192 ATZ/R patients had data


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Treatment Response at Week 48   [ Time Frame: From baseline to Week 48 ]

2.  Secondary:   Treatment Response at Week 48 (TLOVR Algorithm)   [ Time Frame: From baseline to Week 48 ]

3.  Secondary:   Proportion of Patients With VL < 50 Copies/ml   [ Time Frame: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT ]

4.  Secondary:   Proportion of Patients With VL < 400 Copies/ml   [ Time Frame: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT ]

5.  Secondary:   Change in CD4+ Count From Baseline   [ Time Frame: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT ]

6.  Secondary:   Change in Framingham Score From Baseline   [ Time Frame: From baseline to Weeks 48, 96 and 144/EOT ]

7.  Secondary:   Change in Mental Health Summary (MHS) Score From Baseline   [ Time Frame: From baseline to Weeks 48, 96 and 144/EOT ]

8.  Secondary:   Change in Physical Health Summary (PHS) Score From Baseline   [ Time Frame: From baseline to Weeks 48, 96 and 144/EOT ]

9.  Secondary:   Number of Patients Hospitalized   [ Time Frame: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT ]

10.  Secondary:   Non-scheduled Physician Visits   [ Time Frame: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT ]

11.  Secondary:   Genotypic Resistance Associated With Virologic Failure   [ Time Frame: From baseline to Week 48 ]

12.  Secondary:   Treatment-emergent AIDS-defining Illness   [ Time Frame: From baseline to Week 144 ]

13.  Secondary:   Treatment-emergent AIDS-defining Illness Leading to Death   [ Time Frame: From baseline to Week 144 ]

14.  Secondary:   Lipodystrophy   [ Time Frame: From baseline to Week 144 ]

15.  Secondary:   Serum Lipid Abnormalities   [ Time Frame: From baseline to Week 144 ]

16.  Secondary:   Glycaemic Abnormalities   [ Time Frame: From baseline to Week 144 ]

17.  Secondary:   Treatment Response at Week 96   [ Time Frame: From baseline to Week 96 ]

18.  Secondary:   Treatment Response at Week 144   [ Time Frame: From baseline to Week 144 ]

19.  Secondary:   Proportion of Patients With Virological Rebound With VL >=50 Copies/mL After CVR (Confirmed Virological Response) at Week 24, 48, 96, 144   [ Time Frame: at Week 24, 48, 96, 144 ]

20.  Secondary:   Proportion of Patients With Virological Rebound With VL >=400 Copies/mL After CVR at Week 24, 48, 96, 144   [ Time Frame: at Week 24, 48, 96, 144 ]

21.  Secondary:   Proportion of Patients With Virologic Failure at Week 48, 96, 144   [ Time Frame: at Week 48, 96, 144 ]

22.  Secondary:   Time to Treatment Response (First Confirmed VL<50 Copies/mL)   [ Time Frame: baseline to week 144 ]

23.  Secondary:   Time to Loss of Virologic Response (Rebound)   [ Time Frame: Baseline to week 144 ]

24.  Secondary:   Time to Treatment Failure   [ Time Frame: baseline to week 144 ]

25.  Secondary:   Change in the Calculated Glomerular Filtration Rate (GFR) at Week 48, 96 and 144   [ Time Frame: From baseline to Week 48, 96, 144 ]

26.  Secondary:   Proportion of Patients With >= DAIDS Grade 2 Laboratory Abnormalities   [ Time Frame: week 148 ]

27.  Secondary:   Proportion of Patients Reporting Rash of Any Severity   [ Time Frame: week 148 ]

28.  Secondary:   Proportion of Patients Reporting Hepatic Events of Any Severity   [ Time Frame: week 148 ]

29.  Secondary:   Proportion of Patients Reporting CNS (Central Nervous System) Side Effects of Any Severity   [ Time Frame: week 148 ]

30.  Secondary:   Change of Cholesterol Values From Baseline to Week 48, 96, 144   [ Time Frame: baseline to week 48, 96, 144 ]

31.  Secondary:   Changes of Apolipoprotein Values From Baseline to Week 48, 96, 144   [ Time Frame: baseline to week 48, 96, 144 ]

32.  Secondary:   Change of hsCRP From Baseline to Week 48, 96, 144   [ Time Frame: baseline to week 48, 96, 144 ]

33.  Secondary:   Change of Total Triglycerides From Baseline to Week 48, 96, 144   [ Time Frame: baseline to week 48, 96, 144 ]

34.  Secondary:   Change of Total Cholesterol to HDL-cholesterol Ratio From Baseline to Week 48, 96, 144   [ Time Frame: baseline to week 48, 96, 144 ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame 148 weeks
Additional Description No text entered.

Reporting Groups
  Description
Nevirapine QD NVP 400mg QD on a background of the fixed combination Truvada®
Nevirapine BID NVP 200mg BID on a background of the fixed combination Truvada®
Atazanvir/Ritonavir ATZ/r on a background of the fixed combination Truvada®

Serious Adverse Events
    Nevirapine QD   Nevirapine BID   Atazanvir/Ritonavir
Total, serious adverse events       
# participants affected / at risk   25/188 (13.30%)   31/188 (16.49%)   27/193 (13.99%) 
Blood and lymphatic system disorders       
Anaemia † 1       
# participants affected / at risk   0/188 (0.00%)   2/188 (1.06%)   0/193 (0.00%) 
Neutropenia † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Cardiac disorders       
Acute myocardial infarction † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Angina pectoris † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Angina unstable † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Cardiac failure † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Myocardial infarction † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Myopericarditis † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Endocrine disorders       
Goitre † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Eye disorders       
Retinal detachment † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Gastrointestinal disorders       
Constipation † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Inguinal hernia † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Peritonitis † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
General disorders       
Asthenia † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Fatigue † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Multi-organ failure † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Pain † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Puncture site haemorrhage † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Pyrexia † 1       
# participants affected / at risk   1/188 (0.53%)   3/188 (1.60%)   0/193 (0.00%) 
Hepatobiliary disorders       
Cholecystitis † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Cholecystitis acute † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Cholelithiasis † 1       
# participants affected / at risk   0/188 (0.00%)   3/188 (1.60%)   0/193 (0.00%) 
Cholestasis † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Immune system disorders       
Drug hypersensitivity † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Infections and infestations       
Abscess jaw † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Anal abscess † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Anogenital warts † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   5/193 (2.59%) 
Appendicitis † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Candida pneumonia † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Cerebral toxoplasmosis † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Cryptococcosis † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Cytomegalovirus infection † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Gastroenteritis † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
H1N1 influenza † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
HIV infection † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Hepatitis A † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   2/193 (1.04%) 
Herpes zoster † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Meningitis viral † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Neurosyphilis † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Orchitis † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Papilloma viral infection † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Pneumocystis jiroveci pneumonia † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Pneumonia † 1       
# participants affected / at risk   2/188 (1.06%)   0/188 (0.00%)   3/193 (1.55%) 
Postoperative wound infection † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Pulmonary tuberculosis † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Salpingitis † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Sepsis † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Sinusitis † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Subcutaneous abscess † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Tuberculosis † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Urinary tract infection † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Injury, poisoning and procedural complications       
Drug exposure during pregnancy † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Fall † 1       
# participants affected / at risk   1/188 (0.53%)   1/188 (0.53%)   0/193 (0.00%) 
Fracture of penis † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Meniscus lesion † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Multiple injuries † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Rib fracture † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Subdural haematoma † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Upper limb fracture † 1       
# participants affected / at risk   1/188 (0.53%)   2/188 (1.06%)   0/193 (0.00%) 
Investigations       
Alanine aminotransferase increased † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   1/193 (0.52%) 
Aspartate aminotransferase increased † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Blood bilirubin increased † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   1/193 (0.52%) 
Blood creatine phosphokinase increased † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Gamma-glutamyltransferase increased † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Haemoglobin decreased † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Transaminases increased † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Musculoskeletal and connective tissue disorders       
Arthralgia † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Back pain † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Flank pain † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Musculoskeletal stiffness † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Myalgia † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Neck pain † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)       
Basal cell carcinoma † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Bladder neoplasm † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Bone neoplasm † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Hodgkin's disease † 1       
# participants affected / at risk   2/188 (1.06%)   2/188 (1.06%)   0/193 (0.00%) 
Kaposi's sarcoma † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Lung carcinoma cell type unspecified recurrent † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Lung neoplasm malignant † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Lymphoma † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Myelodysplastic syndrome † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Non-Hodgkin's lymphoma † 1       
# participants affected / at risk   0/188 (0.00%)   2/188 (1.06%)   0/193 (0.00%) 
Pancreatic carcinoma † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Nervous system disorders       
Carpal tunnel syndrome † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Cerebellar syndrome † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Cerebrovascular accident † 1       
# participants affected / at risk   0/188 (0.00%)   2/188 (1.06%)   0/193 (0.00%) 
Convulsion † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Epilepsy † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Headache † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   1/193 (0.52%) 
Hypoaesthesia † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Neuralgia † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Neuropathy peripheral † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Psychiatric disorders       
Alcohol abuse † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Depression † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Schizophrenia † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Suicide attempt † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Renal and urinary disorders       
Renal failure † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Renal failure acute † 1       
# participants affected / at risk   1/188 (0.53%)   1/188 (0.53%)   0/193 (0.00%) 
Reproductive system and breast disorders       
Cervical dysplasia † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Ovarian cyst ruptured † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Respiratory, thoracic and mediastinal disorders       
Asthma † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Chronic obstructive pulmonary disease † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Cough † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Dyspnoea † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Interstitial lung disease † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Pleural effusion † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Pleurisy † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Pulmonary oedema † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Skin and subcutaneous tissue disorders       
Rash † 1       
# participants affected / at risk   1/188 (0.53%)   0/188 (0.00%)   0/193 (0.00%) 
Surgical and medical procedures       
Breast prosthesis implantation † 1       
# participants affected / at risk   0/188 (0.00%)   1/188 (0.53%)   0/193 (0.00%) 
Mastoidectomy † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Tympanoplasty † 1       
# participants affected / at risk   0/188 (0.00%)   0/188 (0.00%)   1/193 (0.52%) 
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 14.0




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information